Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Mayo Clinic - Rochester

Neither a doctor nor a teaching hospital

Research payments

$7,798,256

284 payments

Through program year 2025, Mayo Clinic - Rochester is reported as receiving $7,798,256 in research payments, across 284 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $2,342,735 100
2024 Research $2,317,903 83
2023 Research $825,058 49
2022 Research $34,326 4
2020 Research $719 19
2019 Research $2,277,514 29

Breakdown

Who paid Research payments · program years 2019–2025
  1. Genentech, Inc. $2,471,180 108 payments
  2. Novartis Pharmaceuticals Corporation $1,966,497 51 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $1,530,177 11 payments
  4. TESARO, Inc. $655,679 7 payments
  5. Merck Sharp & Dohme Corporation $402,910 11 payments
  6. Galvanize Therapeutics, Inc $257,994 7 payments
  7. Recordati_Rare_Diseases_Inc. $175,977 6 payments
  8. Deciphera Pharmaceuticals Inc. $104,248 14 payments
  9. LivaNova USA, Inc. $74,528 6 payments
  10. AbbVie, Inc. $65,241 14 payments
Studies the money was for Research payments · program years 2019–2025
  1. Morningsun $1,558,620 41 payments
  2. A Randomized Phase II Trial to Evaluate Alisertib Alone or Combined with Fulvestrant in Women with Advanced, Hormone-Receptor Positive (HR+) Breast Cancer $1,024,542 9 payments
  3. 177Lu-Dotatate in patients with inoperable, somatostatin receptor positive, progressive meningioma after external beam radiation $830,768 3 payments
  4. Phase 2 Multicohort Study to Evaluate the Safety and Efficacy of Novel Treatment Combinations in Patients With Recurrent Ovarian Cancer Opal $655,679 7 payments
  5. A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun) $547,677 14 payments
  6. Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma $505,635 2 payments
  7. An Open-Label, Randomized, Phase III Study Comparing 177Lu-Psma-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (Mhspc) $334,184 4 payments
  8. A Randomized, Controlled Study to Evaluate LNP023 (Iptacopan) in Patients With Active ANCA-associated Vasculitis $317,428 2 payments
  9. An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) $274,141 2 payments
  10. Csp018 Affinity $240,001 6 payments
What the money was spent on Research payments · program years 2019–2025
  1. Other $1,386 1 payment

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record